Moderna's Covid-19 vaccine has received full approval from the US Food and Drug Administration (FDA).
The vaccine, named Spikevax, is approved for use in people ages 18 and older, Xinhua news agency reported.
Spikevax meets the FDA's rigorous standards for safety, effectiveness and manufacturing quality required for approval, said the agency in a statement.
"While millions of people have already safely received Covid-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," said Acting FDA Commissioner Janet Woodcock.
"Today's milestone puts us one step closer to altering the course of this pandemic in the US," she said.
Moderna's Covid-19 vaccine is the second one in the US to receive full approval from the FDA. Pfizer's Covid-19 vaccine, Comirnaty, was fully approved for use in people ages 16 and older in August 2021.
Moderna's Covid-19 vaccine has been available under the FDA's emergency use authorization for individuals 18 years of age and older since December 18, 2020.
--IANS
int/shs
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU